SCHEMBL1132885

SCHEMBL1132885

CC(C)(CC(=O)O)n1cccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXA2R P21731 2/20 0.44
HMGCR P04035 1/20 0.44
CHRM1 P11229 1/20 0.44
ADRA1A P35348 1/20 0.44
CYP2C19 P33261 2/20 0.43
HIF1A Q16665 2/20 0.43
CYP2D6 P10635 1/20 0.42
TSHR P16473 1/20 0.42
KDM4E B2RXH2 1/20 0.38
FFAR1 O14842 1/20 0.38
CPT2 P23786 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
TBXAS1 P24557 3/20 0.35
ALDH1A1 P00352 1/20 0.33
POLB P06746 3/20 0.31
NSD2 O96028 1/20 0.31
GRK2 P25098 1/20 0.31
CASP6 P55212 1/20 0.31
CTDSP1 Q9GZU7 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23182611 0.81 SMN1; SMN2 (0.40) CYP2C19HIF1AALDH1A1POLBSMN1; SMN2
SCHEMBL17233622 0.74 CYP2C19 (0.35) TBXA2RHMGCRCHRM1ADRA1ACYP2C19
SCHEMBL23666128 0.71 HMGCR (0.40) TBXA2RHMGCRCHRM1ADRA1ACYP2C19
SCHEMBL14249210 0.71 KDM4E (0.43) TBXA2RHMGCRCHRM1ADRA1ACYP2C19
SCHEMBL7417294 0.71
SCHEMBL2183850 0.69 CYP1A2 (0.30)
.Beta.-Hydroxyisovaleric Acid SCHEMBL8434567 0.69 HMGCR (0.60) TBXA2RHMGCRCHRM1ADRA1ACYP2C19
SCHEMBL18127402 0.68 HMGCR (0.41) TBXA2RHMGCRCHRM1ADRA1ACYP2C19
SCHEMBL24692277 0.68
SCHEMBL95498 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11053242-B2 [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto NEUROCRINE BIOSCIENCES, INC. (US) 2021-07-06 US disclosed
US-20200262834-A1 [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO NEUROCRINE BIOSCIENCES, INC. 2020-08-20 US disclosed
EP-2102317-B1 ADDITIVE, FUEL COMPOSITION, METHOD AND USE INNOSPEC LTD (GB) 2018-10-17 EP disclosed
US-9988382-B2 [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-A]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto NEUROCRINE BIOSCIENCES, INC. (US) 2018-06-05 US disclosed
US-9988382-B2 [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-A]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto NEUROCRINE BIOSCIENCES, INC. (US) 2018-06-05 US disclosed
US-20170349586-A1 [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO NEUROCRINE BIOSCIENCES, INC. 2017-12-07 US disclosed
US-20170349586-A1 [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO NEUROCRINE BIOSCIENCES, INC. 2017-12-07 US disclosed
US-9714246-B2 [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto NEUROCRINE BIOSCIENCES, INC. (US) 2017-07-25 US disclosed
US-9714246-B2 [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto NEUROCRINE BIOSCIENCES, INC. (US) 2017-07-25 US disclosed
US-20160289226-A1 [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO NEUROCRINE BIOSCIENCES, INC. 2016-10-06 US disclosed
WO-2006091592-A1 NAPHTHALENE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR SMITHKLINE BEECHAM CORPORATION (US) 2006-08-31 WO disclosed
EP-1230327-B1 FUEL ADDITIVE FOR THE PREVENTION OF VALVE SEAT RECESSION ASS OCTEL (GB) 2006-06-07 EP disclosed
WO-2005087901-A2 FUEL ADDITIVE COMPOSITION HAVING ANTIKNOCK PROPERTIES INNOSPEC LIMITED (GB) 2005-09-22 WO disclosed
WO-2004055136-A1 USE OF METAL TO PREVENT SPARK PLUGS FOULING FROM IRON THE ASSOCIATED OCTEL COMPANY LIMITED (GB) 2004-07-01 WO disclosed
EP-1047755-B1 FUEL ADDITIVES ASS OCTEL (GB) 2003-04-23 EP disclosed
US-6488725-B1 REGENERATING FILTER TRAP BY ADDING SYNERGISTIC MIXTURE OF IRON COMPOUND AND BARIUM AND/OR STRONTIUM COMPOUND BEFORE OR DURING COMBUSTION; DIESEL ENGINES THE ASSOCIATED OCTEL COMPANY LIMITED (GB) 2002-12-03 US disclosed
EP-1230327-A1 FUEL ADDITIVE FOR THE PREVENTION OF VALVE SEAT RECESSION The Associated Octel Company Limited (GB) 2002-08-14 EP disclosed
WO-2001016257-A1 FUEL ADDITIVE FOR THE PREVENTION OF VALVE SEAT RECESSION THE ASSOCIATED OCTEL COMPANY LIMITED (GB) 2001-03-08 WO disclosed
EP-1047755-A1 FUEL ADDITIVES THE ASSOCIATED OCTEL COMPANY LIMITED (GB) 2000-11-02 EP disclosed
WO-1999036488-A1 FUEL ADDITIVES THE ASSOCIATED OCTEL COMPANY LIMITED (GB) 1999-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160289226-A1 [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO SLC18A2, SLC6A2, SLC18A1 TBXA2R 1405/4885HMGCR 1433/4885CHRM1 327/4885
US-20170349586-A1 [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO SLC18A2, SLC6A2, SLC18A1 TBXA2R 1405/4885HMGCR 1433/4885CHRM1 327/4885
US-11053242-B2 [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto SLC18A2, SLC6A2, SLC18A1 TBXA2R 1405/4885HMGCR 1433/4885CHRM1 327/4885
US-20200262834-A1 [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO SLC18A2, SLC6A2, SLC18A1 TBXA2R 1405/4885HMGCR 1433/4885CHRM1 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.